Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study

• Conditions: Liver Cirrhosis; Acute-On-Chronic Liver Failure; Liver Transplant; Complications

• Registration Number: NCT05036031
• Lead Sponsor: RenJi Hospital

Brief Summary

The definition and diagnostic criteria of acute-on chronic liver failure (ACLF) differed evidently between the East and the West due to the difference in the underlying etiology. Liver transplantation is the most effective treatment to reverse the progress of ACLF and improve the survival rate of patients. The purpose of this study is to explore the accuracy of the two diagnostic criteria of EASL-CLIF and APASL ACLF in assessing the survival rate of patients with liver cirrhosis after LT.

Detailed Description

A retrospective collection and analysis of the preoperative conditions of patients with LT due to cirrhosis in a single center from January 2015 to June 2020 would be conducted, including epidemiological characteristics, etiology, clinical indicators, and short-term (28 days, 90 days) and long-term (1 year, 3 years) survival after LT.

Study Timeline

• Status Verified: 2021-09
• Study Start: 2021-09-01
• Study First Submitted: 2021-09-01
• Study First Submitted QC: 2021-09-01
• Last Update Submitted: 2021-09-01
• Study First Posted: 2021-09-05
• Last Update Posted: 2021-09-05
• Primary Completion: 2021-10-01
• Study Completion: 2021-10-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• patients underwent liver transplantation for cirrhosis
• The diagnosis of ACLF followed APASL and EASL-CLIF definition.

Exclusion Criteria

• Patients with malignant tumor or underwent living donor liver transplantation (LDLT) were excluded.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
3 years overall survival	Up to ~3 years